ARCHIVES

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Cooperative Groups, NCI To Talk About Overlaps

March 14, 1975

8 Centers Awarded Comprehensive Designation

February 15, 1991

NCI Splits Prevention and control Division; Rimer to Direct Division Of Cancer Conrol

July 25, 1997

In Brief: Marasco New ACR President, Barbara Chick VP; Wolmark Named Surgeon In Chief Of Montefiore

October 10, 1986

Breast Cancer Activist, Radiologist Are Added To Special Commission

November 6, 1992

FDA Advisors Uphold Broad Mandate To Limit Use Of ESA Products In Cancer Indications.

May 11, 2007